X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3970) 3970
Book Review (1141) 1141
Publication (199) 199
Book Chapter (25) 25
Conference Proceeding (8) 8
Dissertation (3) 3
Book / eBook (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2987) 2987
humans (2518) 2518
diabetes mellitus, type 2 - drug therapy (1829) 1829
type 2 diabetes (1507) 1507
male (1403) 1403
endocrinology & metabolism (1356) 1356
diabetes (1230) 1230
dipeptidyl-peptidase iv inhibitors - therapeutic use (1229) 1229
hypoglycemic agents - therapeutic use (1170) 1170
dipeptidyl peptidase-4 inhibitor (1163) 1163
female (1073) 1073
glucagon-like peptide-1 (1032) 1032
animals (908) 908
middle aged (878) 878
sitagliptin (875) 875
dipeptidyl peptidase-4 inhibitors (825) 825
pharmacology & pharmacy (780) 780
glucose (727) 727
aged (710) 710
double-blind (672) 672
metformin (670) 670
glycemic control (654) 654
dipeptidyl-peptidase iv inhibitors - pharmacology (627) 627
treatment outcome (613) 613
diabetes mellitus, type 2 - blood (579) 579
insulin (563) 563
hypoglycemic agents (555) 555
diabetes mellitus (553) 553
hypoglycemic agents - adverse effects (540) 540
dipeptidyl-peptidase iv inhibitors - adverse effects (525) 525
adult (517) 517
type-2 diabetes-mellitus (488) 488
type 2 diabetes mellitus (476) 476
care and treatment (469) 469
blood glucose - metabolism (467) 467
safety (465) 465
adamantane - analogs & derivatives (459) 459
drug therapy, combination (440) 440
vildagliptin (437) 437
drug therapy (432) 432
analysis (431) 431
efficacy (431) 431
blood glucose - drug effects (425) 425
dipeptidyl peptidase 4 - metabolism (416) 416
risk factors (413) 413
hypoglycemic agents - administration & dosage (411) 411
internal medicine (410) 410
sitagliptin phosphate (410) 410
dipeptidyl peptidase-4 (403) 403
research (392) 392
beta-cell function (387) 387
hypoglycemic agents - pharmacology (385) 385
mice (380) 380
dipeptidyl-peptidase iv inhibitors - administration & dosage (365) 365
diabetes therapy (363) 363
medicine, general & internal (359) 359
dpp-4 inhibitor (348) 348
dextrose (340) 340
glucagon (339) 339
medicine & public health (337) 337
mellitus (335) 335
linagliptin (330) 330
diabetes mellitus, type 2 - complications (329) 329
metformin - therapeutic use (327) 327
glycated hemoglobin a - metabolism (326) 326
improves glycemic control (323) 323
rats (315) 315
hyperglycemia (309) 309
peptidase (308) 308
glp-1 (306) 306
insulin resistance (295) 295
peptides (293) 293
abridged index medicus (283) 283
diabetes mellitus, type 2 - metabolism (282) 282
adamantane - therapeutic use (276) 276
double-blind method (276) 276
clinical trials (275) 275
hypoglycemia (272) 272
therapy (272) 272
dosage and administration (268) 268
health aspects (263) 263
cardiac & cardiovascular systems (258) 258
medicine, research & experimental (254) 254
dpp-4 inhibitors (253) 253
triazoles - therapeutic use (251) 251
pyrazines - therapeutic use (248) 248
incretin (242) 242
saxagliptin (232) 232
obesity (229) 229
review (223) 223
risk (223) 223
pharmacokinetics (218) 218
oxidative stress (213) 213
studies (212) 212
inflammation (210) 210
diabetes mellitus, type 2 - physiopathology (208) 208
drug-naive patients (206) 206
glycosylated hemoglobin (205) 205
incretins - therapeutic use (202) 202
monotherapy (199) 199
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3854) 3854
German (25) 25
French (24) 24
Korean (19) 19
Japanese (18) 18
Spanish (14) 14
Russian (12) 12
Hungarian (8) 8
Chinese (4) 4
Italian (3) 3
Polish (2) 2
Swedish (2) 2
Czech (1) 1
Danish (1) 1
Dutch (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuropharmacology, ISSN 0028-3908, 09/2013, Volume 72, pp. 291 - 300
Type 2 diabetes (T2D) is one of the major risk factors associated with Alzheimer's disease (AD). Recent studies have found similarities in molecular mechanisms... 
Type 2 diabetes | Wistar rats | Glucagon-like peptide-1 | Amyloid beta | Tau | Inflammatory markers | Hippocampus | OXIDATIVE STRESS | COGNITIVE IMPAIRMENT | CHOLINESTERASE-INHIBITORS | NEUROSCIENCES | INDUCED EXPERIMENTAL DEMENTIA | INTRACEREBROVENTRICULAR INJECTION | AMYLOID-BETA | HYPERPHOSPHORYLATED TAU-PROTEIN | PAIRED HELICAL FILAMENTS | A-BETA | PHARMACOLOGY & PHARMACY | Tumor Necrosis Factor-alpha - metabolism | Antibiotics, Antineoplastic - toxicity | Rats, Wistar | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | tau Proteins - metabolism | Male | Hippocampus - drug effects | Alzheimer Disease - pathology | Dose-Response Relationship, Drug | Interleukin-1beta - metabolism | Amyloid beta-Peptides - metabolism | Exploratory Behavior - drug effects | Adamantane - therapeutic use | Alzheimer Disease - chemically induced | Adamantane - analogs & derivatives | Disease Models, Animal | Dipeptides - therapeutic use | Glucagon-Like Peptide 1 - metabolism | Alzheimer Disease - drug therapy | Rats | Hippocampus - pathology | Maze Learning - drug effects | Gene Expression Regulation - drug effects | Hippocampus - metabolism | Animals | Dogs | Streptozocin - toxicity | Peptides | Streptozocin | Analysis | Amyloid beta-protein | Drugstores | Development and progression | Alzheimer's disease | Pharmaceutical biotechnology | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2012, Volume 59, Issue 3, pp. 265 - 276
The aim of this study was to investigate the antiatherogenic effects of the dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin (DFS). The new class of... 
atherosclerosis | dipeptidyl peptidase-4 inhibitors | endothelium | glucagon-like peptide 1 receptor | receptors | inflammation
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 344 - 351
Aims To compare the sodium-glucose-cotransporter-2 (SGLT-2) inhibitor dapagliflozin with dipeptidyl peptidase-4 (DPP-4) inhibitors with regard to risk... 
cardiovascular disease | type 2 diabetes | DPP | hypoglycaemia | dapagliflozin | diabetes complications | 4 inhibitor | DPP-4 inhibitor | REGISTER | SEVERE HYPOGLYCEMIA | MONOTHERAPY | HEART-FAILURE | PREVALENCE | COMBINATION | METFORMIN TREATMENT | INSULIN | DRUGS | ENDOCRINOLOGY & METABOLISM | DPP-4 INHIBITORS | Diabetic Cardiomyopathies - ethnology | Cardiovascular Diseases - ethnology | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Incidence | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - ethnology | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Female | Glucosides - therapeutic use | Diabetic Angiopathies - prevention & control | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 - metabolism | Kaplan-Meier Estimate | Proportional Hazards Models | Diabetic Angiopathies - ethnology | Sweden - epidemiology | Diabetic Cardiomyopathies - epidemiology | Norway - epidemiology | Denmark - epidemiology | Membrane Transport Modulators - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Type 2 diabetes | Heart | Complications and side effects | Comorbidity | Atrial fibrillation | Glucose | Comparative analysis | Risk factors | Heart attack | Dextrose | Diabetes therapy | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Heart attacks | Peptidase | Mortality | Diabetes mellitus | Hypoglycemia | Patients | Fibrillation | Sodium | Diabetes | Cardiovascular diseases | Health risk assessment | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | DPP‐4 inhibitor | Original | Clinical Medicine | Medical and Health Sciences | Endokrinologi och diabetes | Medicin och hälsovetenskap | Klinisk medicin | Endocrinology and Diabetes
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2012, Volume 59, Issue 3, pp. 265 - 276
Journal Article
Journal Article
Metabolism, ISSN 0026-0495, 2013, Volume 62, Issue 3, pp. 347 - 351
Abstract Aims/hypothesis Glucagon-like peptide-1 (GLP-1) exerts beneficial effects on the cardiovascular system. Here, we examined the effect of sitagliptin, a... 
Endocrinology & Metabolism | Glucagon-like peptide-1 | Monocytes | Inflammatory cytokines | Atherogenic lipoproteins | MACROPHAGES | ENDOCRINOLOGY & METABOLISM | MICE | ATHEROSCLEROTIC LESION | Multivariate Analysis | Triazoles - administration & dosage | Prospective Studies | Cholesterol - blood | Humans | Middle Aged | Pyrazines - administration & dosage | Interleukin-10 - blood | Cholesterol - immunology | Glucagon-Like Peptide 1 - blood | Male | Inflammation - blood | Glucagon-Like Peptide 1 - immunology | Inflammation - drug therapy | Interleukin-6 - blood | Diabetes Mellitus, Type 2 - immunology | Leukocytes, Mononuclear - immunology | Tumor Necrosis Factor-alpha - immunology | Blood Glucose - immunology | Female | Sitagliptin Phosphate | Leukocytes, Mononuclear - drug effects | Inflammation - immunology | Serum Amyloid A Protein - immunology | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Regression Analysis | Diabetes Mellitus, Type 2 - blood | Interleukin-6 - immunology | Diabetes Mellitus, Type 2 - drug therapy | Interleukin-10 - immunology | C-Reactive Protein - immunology | Diabetics | Care and treatment | C-reactive protein | Glucagon | Anti-inflammatory drugs | Low density lipoproteins | Analysis | Insulin resistance | Hypoglycemic agents | Blood lipids | Diabetes | Cholesterol | Index Medicus
Journal Article
by Chen, SM and Zhao, EF and Li, WF and Wang, JH
MEDICINE, ISSN 0025-7974, 12/2017, Volume 96, Issue 48, pp. e8952 - e8952
Background: Previous studies have reported conflicting results for the relationship between dipeptidyl peptidase-4 (DPP-4) inhibitor drugs and acute... 
POPULATION | TRIALS | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | SAXAGLIPTIN | acute pancreatitis | SITAGLIPTIN | meta-analysis | dipeptidyl peptidase-4 inhibitor | THERAPIES | TYPE-2 DIABETES-MELLITUS | Index Medicus | Abridged Index Medicus
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2012, Volume 167, Issue 2, pp. 451 - 457
Journal Article
Journal Article